97 results on '"Perol, M."'
Search Results
2. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study
3. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial
4. Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial
5. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study
6. LBA8 Precision immuno-oncology for advanced non-small cell lung cancer (NSCLC) patients with PD-(L)1 inhibitors resistance (PIONeeR): A phase Ib/IIa clinical trial targeting identified resistance pathways
7. 1806P Clinical characteristics and management of small cell lung cancer long survivors
8. 1382P Vebreltinib efficacy and safety in NSCLC patients with METex14 skipping mutations
9. 1380P PK/PD analysis of pembrolizumab, nivolumab and atezolizumab in NSCLC patients: The PIONeeR trial
10. 1312P Datopotamab deruxtecan (Dato-DXd) vs docetaxel (DTX) in patients (pts) with advanced nonsquamous (NSQ) non-small cell lung cancer (NSCLC) with brain metastases (mets): Results from TROPION-Lung01
11. 1289P Pooled efficacy and safety from 2 pivotal phase II trials of taletrectinib in patients (Pts) with advanced or metastatic ROS1+ non-small cell lung cancer (NSCLC)
12. 1259MO Encorafenib plus binimetinib in patients (pts) with previously untreated BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC): An open-label, multicenter phase II trial (IFCT-1904 ENCO-BRAF)
13. Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer
14. VP2-2021: Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small cell lung cancer (Nsq-NSCLC) with high PD-L1 expression using real-world data
15. LBA12 Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01
16. LBA4 Randomized phase III study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC
17. 147P Non-small cell lung cancer: Artificial intelligence enables the identification of survival signatures complementary to an Immunologically active gene expression signature involving previous therapies
18. 1455P Nivolumab (nivo) resumption in patients with advanced or metastatic non-small cell lung cancer (aNSCLC): Survival outcomes based on France and Germany real-world data (RWD)
19. 1401P Impact of KRAS mutation on non-small cell lung cancer survival outcomes
20. 1373P Efficacy and safety of taletrectinib in patients (Pts) with ROS1+ non-small cell lung cancer (NSCLC): Interim analysis of global TRUST-II study
21. 1407P Characteristics and treatment sequences of patients (pts) with KRAS G12C, other KRAS and non-KRAS advanced or metastatic (AM) non-small cell lung cancer (NSCLC) in the French ESME cohort
22. 1402P Real-world routine KRAS testing practices in France for patients (pts) with advanced or metastatic (AM) non-small cell lung cancer (NSCLC): Data from the ESME cohort
23. 1396P HER2 testing pattern, characteristics of locally advanced or metastatic NSCLC patients by HER2 testing in France
24. 1369P BrigAlec study: Focus on alectinib efficacy after brigatinib exposure in BrigALK2 study (GFPC 02-2019)
25. 1361P Alectinib for treatment-naïve advanced ALK+ NSCLC selected via blood-based NGS: Updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A
26. 1321MO Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic non–small cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02
27. 1314MO TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
28. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer
29. Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC study
30. Cost-minimization analysis of a phase III trial comparing concurrent versus sequential radiochemotherapy for locally advanced non-small-cell lung cancer (GFPC-GLOT 95–01)
31. 1176P Open-label, dose escalation, phase I/II study to assess safety, tolerability, immunogenicity and preliminary clinical activity of the therapeutic cancer vaccine PDC*lung01 with or without anti-programmed death-1 (PD-1) treatment in patients with non-small cell lung cancer (NSCLC)
32. 976P Phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): Registrational data from DESTINY-Lung01
33. Phase II/III blood first assay screening trial (BFAST) in patients (pts) with treatment-naïve NSCLC: Initial results from the ALK+ cohort
34. Crossed looks on lung cancer perception and knowledge from general public and physicians in France: Results of a two-fold survey
35. Final PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC
36. Circulating tumour DNA (ctDNA) analysis depicts mechanisms of resistance and tumour response to BRAF inhibitors in BRAF-mutant non-small cell lung cancer (NSCLC)
37. Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: Updated survival and subgroup analysis from the real-world EVIDENS study
38. Phase II randomized multicenter study evaluating a treatment regimen alternating docetaxel and cisplatin–vinorelbine with a cisplatin–vinorelbine control group in patients with stage IV non-small-cell lung cancer: GFPC 97.01 study
39. LBA45 Primary data from DESTINY-Lung01: A phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC)
40. 1348P Long-term survival and health-related quality of life with nivolumab for previously-treated advanced non-small cell lung cancer (NSCLC): A wide prospective French real-world study (EVIDENS)
41. 1258P MET exon14 skipping in non-small cell lung cancer: Clinicopathological characteristics, treatments, and efficacy of crizotinib according to functional analysis: AFonMET - GFPC study
42. 1200P BrigALK2 study: A multicentric real-world study evaluating brigatinib in ALK positive advanced pre-treated non-small cell lung cancers: Long-term follow-up with focus on lorlatinib efficacy after brigatinib
43. 1842P Molecular testing in older patients treated for an advanced or metastatic non-squamous non-small cell lung cancer
44. Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Français de Pneumo-Cancérologie (GFPC) Protocol 95-1
45. Biomarker-driven access to crizotinib in ALK, MET or ROS1 positive (+) malignancies in adults and children: The French national AcSé program
46. Efficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma: Data from a French multicentric cohort
47. EVIDENS: An observational study of nivolumab-treated patients in advanced non-small cell lung cancer (NSCLC) in a real-world setting: Initial results on 1394 patients
48. Clinical outcomes in patients with advanced NSCLC treated with targeted therapies, with actionable mutations identified by InVisionFirst ctDNA assay
49. 1242P Characteristics of the first 615 patients enrolled in Pacific R: A study of the first real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
50. LBA53 Precision immuno-oncology for advanced non-small cell lung cancer (NSCLC) patients (pts) treated with PD1/L1 immune checkpoint inhibitors (ICIs): A first analysis of the PIONeeR study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.